biologic

Cnj-016

Vaccinia Immune Globulin Intravenous (Human)

Loss of exclusivityMay 2017projected — 12-year biologic exclusivity estimate
CompanyEmergent BioSolutions Canada Inc.

Drug detail

Brand nameCnj-016
Active ingredientVaccinia Immune Globulin Intravenous (Human)
Strength>=50,000U
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMay 2005
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Cnj-016 patent cliff — loss of exclusivity May 2017 | CliffBio